ArticleInternational journal of clinical and experimental pathology2019
L1CAM-positive expression is associated with poorer survival outcomes in resected non-small cell lung cancer patients.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 6 citations in OpenAlex.
- L1CAM signaling through planar cell polarity drives SOX2 expression and lung adenocarcinoma metastasis.Nature communications · 2026Article
- Development of Antibody-Drug Conjugates Targeting L1CAM to Treat Metastatic Cancer.Molecular cancer therapeutics · 2026Article
- L1CAM/CD171 expression in human tumors and its association with tumor phenotype.Acta oncologica (Stockholm, Sweden) · 2025Article
- A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer.Nature communications · 2024Article
- Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma.Therapeutic advances in medical oncology · 2024Article
- L1 cell adhesion molecule high expression is associated with poor prognosis in surgically resected brain metastases from lung adenocarcinoma.Clinics (Sao Paulo, Brazil) · 2022Article
- Transcription Factors Leading to High Expression of Neuropeptide L1CAM in Brain Metastases from Lung Adenocarcinoma and Clinical Prognostic Analysis.Disease markers · 2021Article
- Different Shades of L1CAM in the Pathophysiology of Cancer Stem Cells.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies have found that L1CAM is significantly related to poor survival prognosis of many human cancers, but few studies focused on the prognostic value of L1CAM in lung cancer patients. Therefore, we detected L1CAM protein expression by immunohistochemistry and analyzed associations with survival outcomes of resected non-small cell lung cancer (NSCLC) patients. Overall, a number of 129 patients were enrolled in our study. Totally, 45 (34.9%) out of 129 NSCLC patients had L1CAM-positive expression. L1CAM-positive NSCLC patients had poorer 5-year survival than patients with L1CAM-negative expression by univariate analysis (
Indexed as
Identifiers
31934096PMC6949586W3008923856What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.